S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Scholar Rock (SRRK) Stock Forecast, Price & News

+0.19 (+3.73%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
659,800 shs
Average Volume
380,863 shs
Market Capitalization
$186.75 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SRRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Scholar Rock logo

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.


Scholar Rock announces 25% workforce reduction
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$18.82 million
Book Value
$4.85 per share


Net Income
$-131.80 million
Net Margins
Pretax Margin




Free Float
Market Cap
$186.75 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.83 out of 5 stars

Medical Sector

768th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

119th out of 210 stocks

Analyst Opinion: 3.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions

Is Scholar Rock a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock
or view top-rated stocks.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Scholar Rock

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) announced its quarterly earnings data on Monday, March, 7th. The company reported ($0.97) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.08. The business earned $4.05 million during the quarter, compared to the consensus estimate of $4.33 million. Scholar Rock had a negative net margin of 236.95% and a negative trailing twelve-month return on equity of 59.99%. During the same period last year, the company posted ($2.81) earnings per share.
View Scholar Rock's earnings history

What price target have analysts set for SRRK?

3 brokerages have issued 1-year target prices for Scholar Rock's stock. Their forecasts range from $24.00 to $55.00. On average, they anticipate Scholar Rock's share price to reach $33.60 in the next year. This suggests a possible upside of 535.2% from the stock's current price.
View analysts' price targets for Scholar Rock
or view top-rated stocks among Wall Street analysts.

Who are Scholar Rock's key executives?
Scholar Rock's management team includes the following people:
  • Dr. Nagesh K. Mahanthappa MBA, Ph.D., Interim CEO, Pres & Director (Age 57, Pay $356.22k)
  • Mr. Edward H. Myles M.B.A., MBA, CFO, COO & Treasurer (Age 50, Pay $615.87k) (LinkedIn Profile)
  • Dr. Yung H. Chyung M.D., Chief Medical Officer (Age 46, Pay $613.61k)
  • Dr. Gregory John Carven Ph.D., Chief Scientific Officer (Age 46)
  • Ms. Catherine Hu, VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D., Gen. Counsel & Corp. Sec. (Age 43)
  • Ms. Caryn Parlavecchio, Chief HR Officer (Age 50)
  • Ms. Lisa Amaya Price, Sr. VP of HR
  • Dr. George G. Nomikos M.D., Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
  • Ms. Erin Moore, Sr. VP of Fin. (Age 47)
What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.44%), Bellevue Group AG (6.19%), State Street Corp (4.26%), Vanguard Group Inc. (4.22%), Victory Capital Management Inc. (4.13%) and Northern Trust Corp (0.73%). Company insiders that own Scholar Rock stock include Edward H Myles, Gregory John Carven, Jeffrey S Flier and Michael Gilman.
View institutional ownership trends for Scholar Rock

Which institutional investors are selling Scholar Rock stock?

SRRK stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bellevue Group AG, Citigroup Inc., BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, TD Asset Management Inc., and BNP Paribas Arbitrage SA. Company insiders that have sold Scholar Rock company stock in the last year include Edward H Myles, and Jeffrey S Flier.
View insider buying and selling activity for Scholar Rock
or view top insider-selling stocks.

Which institutional investors are buying Scholar Rock stock?

SRRK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Victory Capital Management Inc., Frazier Life Sciences Management L.P., Goldman Sachs Group Inc., Vanguard Group Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP, and Qube Research & Technologies Ltd.
View insider buying and selling activity for Scholar Rock
or or view top insider-buying stocks.

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $5.29.

How much money does Scholar Rock make?

Scholar Rock has a market capitalization of $186.74 million and generates $18.82 million in revenue each year. The company earns $-131.80 million in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Scholar Rock have?

Scholar Rock employs 145 workers across the globe.

What is Scholar Rock's official website?

The official website for Scholar Rock is www.scholarrock.com.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3860, via email at [email protected], or via fax at 866-493-4935.

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.